Home

Michael S Hearne

CIK 1759910 · Chief Financial Officer · last filed 2026-05-20

Michael S Hearne is a Chief Financial Officer who has filed 107 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for AUPH, was dated May 20, 2026. Across all open-market trades the lifetime net is +$12.8M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions. 55 SEC filings were submitted jointly with PHARMACEUTICAL CO LA JOLLA.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.87M

Companies

3

Total Filings

107

Lifetime Open-Market Net

$12.78M

Filer Profile

Reported Address
4747 EXECUTIVE DRIVE
SUITE 210
SAN DIEGO, CA 92121
Related Filers
PHARMACEUTICAL CO LA JOLLA — 55 joint filings, latest 2022-08-24
TANG CAPITAL MANAGEMENT LLC — 21 joint filings, latest 2022-08-24
TANG CAPITAL PARTNERS LP — 21 joint filings, latest 2022-08-24
KEVIN TANG — 21 joint filings, latest 2022-08-24
John G Lemkey — 12 joint filings, latest 2020-09-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AUPH Chief Financial Officer 116,144 $16.08 $1.87M $0 1 2026-05-20
LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Chief Financial Officer 9,618,120 $6.22 $59.82M $0 45 2022-07-05
Odonate Therapeutics, Inc. (ODT) Delisted Chief Financial Officer 15,517,186 $1.12 $17.38M $12.78M 59 2021-03-17

Recent Filings

107 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-20 AUPH Grant (A) +116,144 $0 EDGAR
2022-08-24 — Mixed — $0
2022-08-24 — Mixed −9,618,120 -$59.92M
2022-07-05 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +236 $640 EDGAR
2022-06-17 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +236 $642 EDGAR
2022-06-02 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +189 $644 EDGAR
2022-05-17 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +188 $641 EDGAR
2022-05-03 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +185 $642 EDGAR
2022-04-18 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +173 $643 EDGAR
2022-04-04 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) +177 $642 EDGAR
Showing 1–10 of 107
Page 1 of 11
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.